嘉應制藥(002198.SZ):股東陳泳洪、黃利兵被財產保全的股份撤銷裁定
格隆匯6月20日丨嘉應制藥(002198.SZ)公佈,公司收到股東陳泳洪、黃利兵提供的由貴陽市中級人民法院(“貴陽中院”)送達的《民事裁定書》([2021]黔01財保09號之一),裁定內容:“一、撤銷本院(2021)黔01財保09號民事裁定;二、解除按照本院(2021)黔01財保09號民事裁定已採取的保全措施”。
2021年5月18日,貴陽中院根據貴州漢方(集團)有限公司的申請作出《民事裁定書》([2021]黔01 財保09 號),裁定訴前財產保全被申請人陳泳洪、黃利兵名下價值125,000,000元人民幣嘉應制藥(股票代碼:002198)股票1926.0401萬股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.